Certainly. We did an initial safety trial with the University of Toronto, and that would have been conducted in April. We published that data, I believe it was in June, and we did additional follow-up safety trials that summer with Charles River Laboratories in Quebec. In conjunction with the University of Toronto, we also did our efficacy trials over the summer in mice and in hamsters.
You asked if we could have done it more quickly with support. Yes, we could have done it more quickly with support. One of the biggest challenges we faced was that we were in lockdown and we had limited access to our own facilities because of the lockdown criteria and we could not be designated an essential service.